Invasive candidiasis and candidemia: From current opinions to future perspectives

Expert Opinion on Investigational Drugs

Volumn 18, Issue 6, 2009, Pages 735-748

  Rueping, Maria J G T ^a   Vehreschild, Joerg Janne ^a   Cornely, Oliver A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Antifungal treatment; Candidemia; Infection; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; HISTONE DEACETYLASE INHIBITOR; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MGCD 290; MICAFUNGIN; MYCOGRAB; PLACEBO; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG INDICATION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOKALEMIA; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TOTAL PARENTERAL NUTRITION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; CANDIDIASIS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; DRUGS, INVESTIGATIONAL; FORECASTING; HUMANS; RISK FACTORS;

EID: 67649628120     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902911440     Document Type: Review

References (113)

1. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-317
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20(1):133-163 (Pubitemid 46167771)
3. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37(5):634-643
4. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26(6):540-547
5. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24(6):1122-1128
6. Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 2003;82(5):309-321
7. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33(2):177-186
8. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3(11):685-702 (Pubitemid 37345347)
9. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42(4):1519-1527
10. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181(1):309-316 (Pubitemid 30049062)
11. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149(10):2349-2353
12. Martino P, Girmenia C, Micozzi A, et al. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994;13(10):797-804 (Pubitemid 24359435)
13. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43(4):1829-1835 (Pubitemid 40491227)
14. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999;29(5):1164-1170
15. Diekema DJ, Pfaller MA. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004;25(8):624-626 (Pubitemid 39095042)
16. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004;23(10):739-744 (Pubitemid 39517847)
17. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005;43(3):235-243 (Pubitemid 40867497)
18. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005;41(Suppl 6):S389-93 (Pubitemid 41266739)
19. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann surgery 2001;233(4):542-548
20. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34(3):730-737
21. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007;26(4):271-276 (Pubitemid 46572022)
22. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220(6):751-758
23. Dupont H, Bourichon A, Paugam-Burtz C, et al. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003;〉31(3):752-757
24. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002;40(9):3489-3492 (Pubitemid 34977475)
25. Laupland KB, Gregson DB, Church DL, et al. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005;56(3):532-537 (Pubitemid 41264132)
26. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003;9(8):985-990
27. Sandven P, Bevanger L, Digranes A, et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006;44(6):1977-1981
28. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005;43(9):4434-4440 (Pubitemid 41298224)
29. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40(4):1298-1302 (Pubitemid 34279892)
30. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005;49(11):4555-4560
31. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008;29(10):978-980
32. Bougnoux ME, Kac G, Aegerter P, et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 2008;34(2):292-299
33. Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect 2005;11(11):908-913
34. Marchetti O, Bille J, Fluckinger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-320
35. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37(9):1172-1177
36. Hadley S, Lee WW, Ruthazer R, Nasraway SA Jr. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Crit Care Med 2002;30(8):1808-1814 (Pubitemid 34879596)
37. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002;113(6):480-485 (Pubitemid 35335800)
38. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148(12):2642-2645
39. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41(9):1232-1239
40. Puzniak L, Teutsch S, Powderly W, Polish L. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 2004;25(8):628-633
41. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35(5):627-630
42. Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008;112(11):2493-2499
43. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45(6):1735-1745
44. Available from: 〈http://www.ncbi.nlm.nih.gov/Taxonomy/〉; The NCBI Taxonomy Homepage [last accessed 14 April 2009]
45. Richet H, Roux P, Des Champs C, et al. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002;8:405-412
46. Tortorano AM, Biraghi E, Astofi A, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002;51:297-304 (Pubitemid 38001880)
47. Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003;52:71-77 (Pubitemid 36850088)
48. Hsueh PR, Lau YJ, Chuang YC, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005;49(2):512-517
49. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44(3):760-763
50. Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999;34(4):281-286
51. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359(9312):1135-1144 (Pubitemid 34270742)
52. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37(9):1847-1849
53. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004;42:3142-3146 (Pubitemid 38938071)
54. Klevay MJ, Ernst EJ, Hollanbaugh JL, et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008;60(3):273-277
55. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007;51(5):1818-1821
56. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34(1):7-14
57. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46(12):1813-1821
58. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1: 〉;3)-beta-D-glucan assay for the diagnosis of invasive fungal infections: a study based on autopsy cases from 6 years. Clin Infect Dis 2008;46(12):1813- 1821
59. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1: 〉;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41(5):654-659
60. Obayashi T, Yoshida M, Mori T, et al. Plasma (1: 〉;3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345(8941):17-20
61. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999;27(6):1066-1072
62. Swoboda SM, Merz WG, Lipsetta PA. Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect 2003 Winter;4(4):345-354 (Pubitemid 38195784)
63. Garbino J, Lew DP, Romand JA, et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002;28(12):1708-1717
64. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005;31(11):1479-1487 (Pubitemid 41598657)
65. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006;57(4):628-638
66. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006;(1):CD004920
67. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003;101(9):3365-3372 (Pubitemid 36857916)
68. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34(6):730-751
69. Kern WV, Beyer J, Bohme A, et al. Prophylaxis of infection in neutropenic patients. Guidelines of the Working Party on Infections in Hematology and Oncology. Dtsch Med Wochenschr 2000;125(51-52):1582-1588
70. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326(13):845-851
71. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171(6):1545-1552
72. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138(9):705-713
73. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103(4):1527-1533
74. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006;57(2):317-325 (Pubitemid 43160176)
75. Glasmacher A, Prentice A. Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy. Clin Microbiol Infect 2006;12(Suppl 7):84-90 (Pubitemid 44756312)
76. Farowski F, Vehreschild JJ, Cornely OA. Posaconazole: a next-generation triazole antifungal. Future Microbiol 2007;2:231-243 (Pubitemid 47180920)
77. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-359 (Pubitemid 46148777)
78. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-347 (Pubitemid 46148776)
79. Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55(5):445-449 (Pubitemid 47628350)
80. Wingard JR, Carter SL, Walsh TJ, et al. Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients. ASH Annual Meeting; 2007; Atlanta; 2007
81. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39(10):1407-1416
82. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49(4):1331-1336
83. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50(1):143-147
84. Mattiuzzi GN, Alvarado G, Kantarjian HM. Intravenous Voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). 46th American Society of Hematology Annual Meeting; 2004; San Diego; 2004
85. Cruciani M, Serpelloni G. Management of Candida infections in the adult intensive care unit. Expert Opin Pharmacother 2008;9(2):175-191 (Pubitemid 351242512)
86. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004;32(12):2443-2449
87. Golan Y, Wolf MP, Pauker SG, et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 2005;143(12):857-869
88. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340(10):764-771
89. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346(4):225-234 (Pubitemid 34438861)
90. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351(14):1391-1402 (Pubitemid 39288165)
91. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331(20):1325-1330
92. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366(9495):1435-1442
93. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-2029 (Pubitemid 35461658)
94. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369(9572):1519-1527
95. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45(7):883-893
96. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-2482 (Pubitemid 46919773)
97. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003;47(7):2208-2216
98. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006;42(10):1404-1413
99. Herbrecht R, Fohrer C, Nivoix Y. Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 2006;43(8):1083; author reply-4 (Pubitemid 44631113)
100. Diekema DJ, Messer SA, Besterman JM, Pfaller MA. Combination testing of MGCD290, a fungal histone deacetylase inhibitor, with azole antifungals against a large collection of clinical fungal isolates (M2129). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington, USA; 2008
101. Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008;52(4):1396-1400
102. Warn PA, Parmer A, Jayesh M, et al. Pharmacokinetics (PK) and Pharmacodynamics (PD) of Isavuconazole in a Murine Model of Disseminated Candidiasis (DC) (M-2140). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington, USA; 2008
103. Cornely O, Böhme A, Heep M, et al. Pharmacokinetics, Safety and Tolerability Results of a Dose Escalation Study of Isavuconazole in Neutropenic Patients (M-2137). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington, USA; 2008
104. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00413218?term=isavuconazole&rank=1. 2008 [Cited 12/06/2008]
105. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43(1):25-31
106. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49(9):3640-3645 (Pubitemid 41233011)
107. Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin Infect Dis 2001;32(11):1602-1607 (Pubitemid 32458728)
108. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-535
109. Herbrecht R, Flückiger U, Gachot B, et al. Update ECIL-2 2007. 2007; Available from: http://www.sginf.ch/ssi-home/guidelines/otherpapers/op014.pdf [Cited 13.01.2007]
110. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006;42(2):244-251 (Pubitemid 43054198)
111. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008;36(7):2034-2039
112. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Update 2007;10(3):121-130 (Pubitemid 47031054)
113. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008;46(3):842-849